8-K: Annovis Bio Secures NYSE Acceptance for Listing Compliance Plan, Averting Delisting Threat

Annovis Bio, Inc. announced that the New York Stock Exchange has accepted its plan to regain compliance with minimum market capitalization and stockholders' equity listing standards, granting an 18-month cure period.

Summary

• Annovis Bio, Inc. (NYSE: ANVS) received notification on June 19, 2025, that the New York Stock Exchange (NYSE) accepted its previously submitted plan to regain compliance with the NYSE's continued listing standards.
• The non-compliance issues relate to minimum market capitalization and stockholders' equity.
• The NYSE granted the Company an 18-month period, starting from the initial Notice of Noncompliance dated March 26, 2025, to regain full compliance.
• As part of the accepted plan, Annovis Bio is required to provide the NYSE with quarterly updates on its progress towards the outlined goals and initiatives.
• The Company expects its common stock to continue trading on the NYSE during this 18-month Plan Period, contingent upon its adherence to the plan and compliance with other applicable NYSE listing standards.
• This notification from the NYSE does not impact the Company's business operations or its reporting requirements with the U.S. Securities and Exchange Commission.

Sentiment

Score: 7

Explanation: The sentiment is positive because the company successfully had its compliance plan accepted by the NYSE, mitigating the immediate risk of delisting. However, the underlying non-compliance issue still exists, and the company must execute the plan over the next 18 months, preventing a 'strong buy' sentiment.

Positives

• The NYSE accepted Annovis Bio's plan to regain listing compliance, removing the immediate threat of delisting.
• The Company has been granted an 18-month period to achieve compliance, providing ample time to execute its strategy.
• Annovis Bio's stock is expected to continue trading on the NYSE during the compliance period, maintaining market access and liquidity.
• The acceptance of the plan does not affect the Company's ongoing business operations or its SEC reporting obligations.

Negatives

• Annovis Bio was previously non-compliant with NYSE listing standards regarding minimum market capitalization and stockholders' equity.
• The Company is now operating under an 18-month compliance plan, requiring ongoing monitoring and reporting to the NYSE.

Risks

• The Company's ability to successfully execute the accepted plan and regain full compliance with NYSE listing standards within the 18-month cure period.
• The risk of potential suspension of trading of the Company's common stock on the NYSE if compliance is not achieved or the plan is not adhered to.
• Regional, national, or global political, economic, business, competitive, market, and regulatory conditions could impact the Company's ability to meet compliance requirements.
• Risks regarding the Company's ability to manage inventory or anticipate consumer demand (boilerplate risk, less relevant to biotech).
• Changes in consumer confidence and spending (boilerplate risk, less relevant to biotech).
• The competitive environment in which the Company operates.
• Failure to open new profitable stores or successfully enter new markets (boilerplate risk, less relevant to biotech).

Future Outlook

Annovis Bio expects its common stock to continue to be listed and traded on the New York Stock Exchange during the 18-month Plan Period, provided the Company adheres to the accepted plan and complies with all other applicable NYSE continued listing standards.

Management Comments

• Annovis Bio, Inc. announced that it received notification from the New York Stock Exchange that the NYSE has accepted the Company's previously-submitted plan to regain compliance with the NYSE's continued listing standards.

Industry Context

Annovis Bio is a late-stage clinical drug platform company focused on pioneering therapies for neurodegenerative diseases like Alzheimer's and Parkinson's. This announcement primarily addresses a corporate governance and listing compliance issue rather than a direct drug development milestone, though maintaining NYSE listing is crucial for a biotech company's access to capital and investor visibility.

Stakeholder Impact

• Shareholders: The acceptance of the plan reduces the immediate risk of delisting, which could stabilize or positively impact the stock price by removing uncertainty. Continued listing ensures liquidity and market access.
• Employees: The announcement states that the notification does not affect the Company's business or operations, suggesting stability for employees.

Next Steps

• Annovis Bio is required to provide the NYSE with quarterly updates regarding its progress towards the goals and initiatives outlined in the accepted plan.
• The Company must adhere to the accepted plan and continue to comply with other applicable NYSE continued listing standards throughout the 18-month Plan Period.

Key Dates

Recommendation

Keywords

Annovis Bio, ANVS, NYSE, listing compliance, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, biotechnology, drug development, SEC filing, 8-K